Vittorio Studiale: Impressive pathological response rate with neoadjuvant BOT/BAL in MSS CRC
Jun 28, 2024, 13:09

Vittorio Studiale: Impressive pathological response rate with neoadjuvant BOT/BAL in MSS CRC

Vittorio Studiale, Medical Oncology Resident at University Hospital of Pisa, shared on X:

“Impressive pathological response rate (71%, pCR 35%) with neoadjuvant BOT/BAL in MSS colorectal cancer from the update of NEST-1 trial.”

Source: Vittorio Studiale/X